Moberg Pharma AB (FRA:MB8) Ending Cash Position: €20.66 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:MB8 Moberg Pharma AB FRA:MB8
36 GF Score
Price €0.83
! 1 Warning Sign
View Full Analysis

What is Moberg Pharma AB Ending Cash Position?

Moberg Pharma AB FRA:MB8 -0.60% 36 Ending Cash Position is €20.66 Mil as of Mar. 2026. GuruFocus rates FRA:MB8 with a GF Score™ of 36/100. The stock has 1 warning sign investors should review.

Moberg Pharma AB's Ending Cash Position for the quarter that ended in Mar. 2026 was €20.66 Mil.

Moberg Pharma AB's quarterly Ending Cash Position declined from Sep. 2025 (€21.47 Mil) to Dec. 2025 (€21.22 Mil) and declined from Dec. 2025 (€21.22 Mil) to Mar. 2026 (€20.66 Mil).

Moberg Pharma AB's annual Ending Cash Position declined from Dec. 2022 (€11.42 Mil) to Dec. 2023 (€5.41 Mil) but then increased from Dec. 2023 (€5.41 Mil) to Dec. 2024 (€25.50 Mil).

Moberg Pharma AB Ending Cash Position Related Terms

Moberg Pharma AB Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Moberg Pharma AB's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Moberg Pharma AB Ending Cash Position Chart

Moberg Pharma AB Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec21 Dec22 Dec23 Dec24
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.78 10.00 11.42 5.41 25.50

Moberg Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.55 23.13 21.47 21.22 20.66
FRA:MB8
36GF Score
Moberg Pharma AB FRA:MB8
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Moberg Pharma AB Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Moberg Pharma AB's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=5.265+20.233
=25.50

Moberg Pharma AB's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=21.44+-0.784
=20.66

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of €20.66 Mil mean?
Moberg Pharma AB (FRA:MB8) has a Ending Cash Position of €20.66 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Moberg Pharma AB and its competitors.
Is Moberg Pharma AB's Ending Cash Position too high?
Moberg Pharma AB's current Ending Cash Position is €20.66 Mil. Overall, Moberg Pharma AB has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Moberg Pharma AB's Ending Cash Position compare to ZTS?
Moberg Pharma AB's Ending Cash Position of €20.66 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Drug Manufacturers company?
A good Ending Cash Position depends on the Drug Manufacturers industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Moberg Pharma AB and its competitors. Moberg Pharma AB's current Ending Cash Position is €20.66 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moberg Pharma AB stock overvalued right now?
Moberg Pharma AB (FRA:MB8) has a current Ending Cash Position of €20.66 Mil. The current Ending Cash Position is €20.66 Mil. Moberg Pharma AB's overall GF Score™ is 36/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Moberg Pharma AB (FRA:MB8), the current Ending Cash Position is €20.66 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Moberg Pharma AB Business Description

Other Exchanges MBGPF:USAMOB:Sweden
Address Gustavslundsvagen 42, 5th Floor, Bromma, Stockholm, SWE, SE-167 51
Moberg Pharma AB is a Swedish pharmaceutical company which develops and commercializes proprietary pharmaceuticals based on proven substances. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Its geographic areas are Europe, the Americas, and Rest of the world.
36GF Score

Get the complete analysis for FRA:MB8

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.83
Price